The aim of the study was to estimate and correlate circulating levels of
renalase, vascular adhesion protein-1 (VAP-1),
catecholamines in patients with
primary hypertension. The
renalase, VAP-1, and
catecholamines concentration was estimated in 121 hypertensive patients. The correlation between
renalase, VAP-1 levels and
catecholamine concentration in blood, blood pressure control, pharmacological
therapy, and medical history were taken in to consideration. The median office blood pressure was 145.5/86 mm Hg and was significantly higher than the median home blood pressure measurement value, which was 135/80 mm Hg, P < .05. Circulating
renalase and VAP-1 (Me 9.57 μg/mL and Me = 326.7 ng/mL) levels were significantly higher in patients with
hypertension comparing to healthy individuals (3.83 μg/mL and 248.37 ng/mL, P < .05). The correlation between
renalase and noradrenalin concentration in blood was observed (r = 0.549; P < .05), also the correlation between VAP-1 and
noradrenaline was noticed (r = 0.21, P = .029).
Renalase level was higher in patients with
coronary artery disease and correlated with decreased ejection fraction. VAP-1 concentration correlated also with left ventricular ejection fraction (r = -0.23, P = .013). Hypertensive patients with
diabetes mellitus had almost statistically significant higher VAP-1 concentration compared with hypertensive patients without
diabetes mellitus (Me = 403.22 ng/mL vs. Me = 326,68 ng/mL, P = .064). In multiple regression analysis,
renalase was predicted by plasma
dopamine and
norepinephrine as also diastolic office blood pressure and left ventricle ejection fraction. Circulating
renalase and VAP-1 levels are elevated in patients with poor blood pressure control. Its correlation with noradrenalin concentration need further studies to find out the role of
renalase as also VAP-1 in pathogenesis and treatment of
hypertension.